本品是一类非洋地黄强心甙,又非儿茶酚胺类的新型正性肌力药物,由美国Sterling制药厂在70年代研究开发的。它能抑制心脏的磷酸二酯酶,产生正性收缩和外周血管扩张作用。动物实验和临床观察均证明该药能使心力衰竭的心脏增加心输出量及dp/dtmax,降低氧耗与提高患者运动耐力,对心率、心律、心电图及动脉平均压均无明显变 This product is a group of non-digitalis glycosides, non-catecholamines new inotropic drugs, the United States Sterling Pharmaceutical Factory in the 1970s research and development. It inhibits the heart’s phosphodiesterase, producing positive systolic and peripheral vasodilation. Animal experiments and clinical observations have proved that the drug can make the heart of heart failure to increase cardiac output and dp / dtmax, reduce oxygen consumption and improve patient endurance, heart rate, heart rate, electrocardiogram and arterial mean pressure were not significantly changed